JP2021500926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500926A5 JP2021500926A5 JP2020543394A JP2020543394A JP2021500926A5 JP 2021500926 A5 JP2021500926 A5 JP 2021500926A5 JP 2020543394 A JP2020543394 A JP 2020543394A JP 2020543394 A JP2020543394 A JP 2020543394A JP 2021500926 A5 JP2021500926 A5 JP 2021500926A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding molecule
- cancer
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1718101.7A GB201718101D0 (en) | 2017-11-01 | 2017-11-01 | CD47 and CD33 Antigen-binding molecules |
| GB1718101.7 | 2017-11-01 | ||
| GBGB1720425.6A GB201720425D0 (en) | 2017-12-07 | 2017-12-07 | CD47 and CD33 antigen-binding molecules |
| GBGB1720426.4A GB201720426D0 (en) | 2017-12-07 | 2017-12-07 | CD47 and BCMA antigen-binding molecules |
| GB1720425.6 | 2017-12-07 | ||
| GB1720426.4 | 2017-12-07 | ||
| PCT/EP2018/079931 WO2019086573A1 (en) | 2017-11-01 | 2018-11-01 | Cd47 antigen-binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500926A JP2021500926A (ja) | 2021-01-14 |
| JP2021500926A5 true JP2021500926A5 (https=) | 2021-12-09 |
Family
ID=64316482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543394A Pending JP2021500926A (ja) | 2017-11-01 | 2018-11-01 | Ｃｄ４７抗原結合分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220298254A1 (https=) |
| EP (1) | EP3704157A1 (https=) |
| JP (1) | JP2021500926A (https=) |
| KR (1) | KR20200079511A (https=) |
| CN (1) | CN111417653A (https=) |
| AU (1) | AU2018358004A1 (https=) |
| CA (1) | CA3080860A1 (https=) |
| SG (1) | SG11202003943YA (https=) |
| WO (1) | WO2019086573A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018358004A1 (en) | 2017-11-01 | 2020-05-28 | Hummingbird Bioscience Pte. Ltd. | CD47 antigen-binding molecules |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
| PH12022550489A1 (en) * | 2019-09-03 | 2022-12-12 | Akeso Biopharma Inc | Anti-cd47 monoclonal antibody and use thereof |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| US20240294635A1 (en) * | 2020-04-02 | 2024-09-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antigen-binding polypeptide binding to cd47, and use thereof |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| KR102557016B1 (ko) * | 2020-09-22 | 2023-07-20 | 비피진 주식회사 | 암 치료를 위한 cd47 바인더 및 리포좀 복합체 |
| US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
| CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20240269278A1 (en) * | 2021-09-30 | 2024-08-15 | Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group | Anti-cd47 antibody for combined treatment of blood tumor |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN116063579B (zh) * | 2022-11-17 | 2026-02-27 | 安徽医科大学 | 一种靶向人cd47的嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及其应用 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2771336C (en) | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| KR102100388B1 (ko) | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| DK3725807T3 (da) | 2012-12-03 | 2026-01-12 | Novimmune Sa | Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| CA2939411A1 (en) | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| PT3402820T (pt) * | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| EP3454900A4 (en) | 2016-05-09 | 2020-01-29 | Celgene Corporation | CD47 ANTIBODIES AND METHODS OF USE |
| CN105950561A (zh) | 2016-05-26 | 2016-09-21 | 江苏杰晟生物科技有限公司 | 一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品 |
| AU2017332960B2 (en) * | 2016-10-20 | 2019-09-12 | I-Mab Biopharma Us Limited | Novel CD47 monoclonal antibodies and uses thereof |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| AU2018358004A1 (en) | 2017-11-01 | 2020-05-28 | Hummingbird Bioscience Pte. Ltd. | CD47 antigen-binding molecules |
-
2018
- 2018-11-01 AU AU2018358004A patent/AU2018358004A1/en not_active Abandoned
- 2018-11-01 JP JP2020543394A patent/JP2021500926A/ja active Pending
- 2018-11-01 WO PCT/EP2018/079931 patent/WO2019086573A1/en not_active Ceased
- 2018-11-01 EP EP18803566.1A patent/EP3704157A1/en not_active Withdrawn
- 2018-11-01 CA CA3080860A patent/CA3080860A1/en active Pending
- 2018-11-01 US US16/760,899 patent/US20220298254A1/en not_active Abandoned
- 2018-11-01 SG SG11202003943YA patent/SG11202003943YA/en unknown
- 2018-11-01 CN CN201880071849.4A patent/CN111417653A/zh active Pending
- 2018-11-01 KR KR1020207014915A patent/KR20200079511A/ko not_active Ceased
-
2022
- 2022-06-22 US US17/847,020 patent/US11685789B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500926A5 (https=) | ||
| Nakayama et al. | Claudin 18.2 as a novel therapeutic target | |
| JP2021511811A5 (https=) | ||
| FI3802608T3 (fi) | Cd3-vasta-aineita ja niiden käyttötapoja | |
| Soleimani Samarkhazan et al. | Unveiling the potential of CLL-1: a promising target for AML therapy | |
| Jiang et al. | CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia | |
| Guo et al. | Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment | |
| Czystowska-Kuzmicz et al. | The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer | |
| Nagpal et al. | Pediatric Hodgkin lymphoma–biomarkers, drugs, and clinical trials for translational science and medicine | |
| JP2020516305A5 (https=) | ||
| RU2017132214A (ru) | Анти-pvrig антитела и способы применения | |
| JP2021502810A5 (https=) | ||
| Wang et al. | A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma | |
| JP2013539468A5 (https=) | ||
| JP2019512242A5 (https=) | ||
| JP2015524399A5 (https=) | ||
| JP2013529183A5 (https=) | ||
| JP2022548764A5 (https=) | ||
| JP2013166763A5 (https=) | ||
| JP2012500814A5 (https=) | ||
| JP2017526339A5 (https=) | ||
| FI4445958T3 (fi) | Melanooman yhdistelmähoito | |
| JP2021528047A5 (https=) | ||
| Słomka et al. | Extracellular Vesicles and Circulating Tumour Cells-complementary liquid biopsies or standalone concepts? | |
| JP2008508858A5 (https=) |